I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Myopic Macular Degeneration and Pathologic Myopia
Understanding Pathologic Myopia
Pathologic myopia develops when the eye grows too long, placing excessive mechanical stress on the delicate tissues at the back of the eye. This is a very different problem from the ordinary nearsightedness that glasses or contact lenses correct.
In pathologic myopia, the eyeball grows longer than normal, typically exceeding 26 millimeters in axial length (the front-to-back measurement of the eye). This degree of elongation causes the retina, choroid (the blood vessel layer behind the retina), and sclera (the white outer wall of the eye) to become progressively thinner and more fragile. The choroid, which delivers blood and nutrients to the outer retina, becomes extremely thin in pathologic myopia, compromising its ability to nourish the retinal cells responsible for your central vision.
Posterior staphyloma is an outward bulging of the back wall of the eye caused by the chronic stretching forces of pathologic myopia. It is present in approximately half of patients with this condition and is closely associated with choroidal thinning. The irregular curvature of the eye wall creates uneven pressure on the retinal surface and contributes to mechanical forces that can damage the macula (the central part of the retina responsible for sharp, detailed vision). The presence of a posterior staphyloma indicates more advanced disease and a higher risk of progressive macular complications over time.
Lacquer cracks are linear breaks in Bruch's membrane (a thin structural layer beneath the retinal pigment epithelium, or RPE) and the overlying RPE cells. As the back wall of the eye stretches, these layers can crack under the mechanical strain, appearing as yellowish lines on examination of the retina. Lacquer cracks are clinically significant because they create weak points through which abnormal new blood vessels can grow into the space beneath the retina. Eyes with lacquer cracks carry a notably higher risk of developing myopic choroidal neovascularization compared to eyes with other types of myopic maculopathy.
Complications That Threaten Vision
Pathologic myopia can give rise to several serious complications that affect central vision. Understanding these complications helps explain why regular monitoring and prompt treatment matter so much in managing this condition.
Myopic choroidal neovascularization (CNV) occurs when abnormal new blood vessels grow through breaks in Bruch's membrane and extend into the space beneath the retina. These fragile vessels leak fluid and blood, causing swelling and damage to the photoreceptors (the light-sensitive cells) in the macula. Myopic CNV is one of the leading causes of central vision loss in younger and middle-aged adults with high myopia.
Compared to CNV in age-related macular degeneration, myopic CNV tends to be smaller in size and typically responds well to treatment with fewer injections, particularly when it is detected and treated early.
Progressive macular atrophy refers to the gradual loss of RPE cells and photoreceptors in the macular area. As the choroid thins, the RPE cells lose their blood supply and slowly deteriorate, creating expanding patches of atrophy. Atrophy can also develop around the site of previously treated and resolved CNV. Research has shown that myopic atrophic maculopathy progresses in more than half of affected eyes over roughly a decade of follow-up.
This slow but persistent loss of retinal tissue is the primary cause of long-term visual decline in pathologic myopia. There are currently limited options to reverse it, so management focuses on monitoring, treating associated complications when they arise, and providing low vision support when it becomes needed.
Myopic traction maculopathy describes a range of changes caused by tractional (pulling) forces on the macula in an overly elongated eye. These forces can produce macular retinoschisis (splitting of the retinal layers into two separate sheets), foveal detachment (the very center of the retina lifting away from underlying tissue), lamellar macular holes, or full-thickness macular holes. The traction can originate from the vitreous gel, the internal limiting membrane (a thin tissue layer on the retinal surface), or from the mechanical mismatch between the elongated scleral shell and the retina. Careful evaluation is needed to determine whether and when surgical intervention is the right choice.
Who Is at Risk?
Pathologic myopia affects a meaningful proportion of highly nearsighted individuals. Knowing the risk factors helps both patients and their care teams make informed decisions about how frequently to monitor and when to be most vigilant for symptoms.
Pathologic myopia occurs across all ethnic groups, though it appears somewhat more frequently in East Asian populations. The condition tends to become more clinically apparent with increasing age, even though the underlying nearsightedness typically develops during childhood or adolescence. Men and women are affected at similar rates. The growing global prevalence of myopia, driven in part by increased near-work activity and reduced time spent outdoors, is expected to increase the number of people at risk for pathologic changes in coming decades.
The most important risk factor is progressive axial elongation paired with a high degree of myopia. Additional factors that raise the risk of macular complications include:
- Presence of a posterior staphyloma
- Lacquer cracks in the posterior pole of the eye
- Early onset of high myopia during childhood
- Family history of pathologic myopia or myopic macular disease
- Prior CNV in one eye, which raises the risk of CNV developing in the fellow eye
Once degenerative changes begin, they tend to progress over time rather than remain stable on their own, making consistent retinal monitoring essential throughout life.
Recognizing the Symptoms
Different complications of pathologic myopia produce different patterns of visual symptoms. Recognizing which symptoms are urgent versus gradual helps you know when to call your retina specialist right away and when a scheduled visit is appropriate.
When choroidal neovascularization develops, patients typically notice a fairly rapid change in central vision. Common symptoms include:
- Straight lines appearing wavy or bent (a symptom called metamorphopsia)
- A gray or dark spot appearing in the center of vision
- Sudden difficulty reading, seeing fine detail, or recognizing faces
- A noticeable and relatively quick decrease in visual sharpness
These symptoms often develop over a short period of time and should prompt urgent evaluation rather than a watch-and-wait approach.
Macular atrophy causes a more gradual visual decline that unfolds over months to years. You may notice increasing difficulty with reading, recognizing faces, or performing tasks that require sharp central focus. A central blind spot (called a scotoma) may slowly enlarge over time. Because the change is gradual, some patients do not notice how much their vision has shifted until it is formally assessed at a retinal visit.
Myopic traction maculopathy may cause blurred or distorted central vision and a gradual decrease in visual acuity. Some patients have significant structural changes on imaging but relatively mild symptoms, while others notice meaningful visual distortion. A sudden and sharp worsening of central vision can indicate that a full-thickness macular hole has developed, which typically requires prompt surgical attention. Regular OCT imaging is the most reliable way to detect traction changes early, before they cause severe visual loss.
Diagnosis and Imaging
Diagnosing and monitoring pathologic myopia involves a thorough retinal examination combined with advanced imaging studies. A complete picture of the macula guides decisions about when to treat, which treatment to use, and how frequently to follow up.
Your retina specialist will assess your visual acuity, the degree of nearsightedness, and perform a dilated examination of the retina. During this examination, the specialist looks for the characteristic features of pathologic myopia including posterior staphyloma, lacquer cracks, areas of macular atrophy, signs of active CNV, and any evidence of tractional changes at the macula.
Optical coherence tomography (OCT) is one of the most important tools for evaluating myopic macular disease. OCT uses light waves to create detailed, cross-sectional images of the retinal layers, allowing your care team to see structural changes that would not be visible on examination alone. OCT can detect subretinal fluid from active CNV, measure the extent of macular atrophy, and identify tractional changes such as retinoschisis or foveal detachment. OCT angiography, an advanced form of this technology that images retinal blood flow without a dye injection, can help distinguish active CNV from a simple lacquer crack hemorrhage. Serial OCT scans performed over time allow even subtle changes to be tracked reliably.
Depending on your specific findings, additional imaging may be recommended. Fluorescein angiography (an imaging study using an injected dye to highlight retinal blood vessels) helps characterize active CNV and guide treatment planning. Fundus autofluorescence imaging maps areas of RPE damage and monitors their growth over time. Ocular ultrasound may be used to evaluate the shape and curvature of the posterior wall of the eye, particularly to assess posterior staphyloma. Together, these imaging tools provide a comprehensive and individualized picture of your macular health.
Treatment Options
Treatment for pathologic myopia depends on which complication is present, how active it is, and the individual patient's overall eye health. Our retina specialists tailor each treatment plan based on a thorough review of your imaging, visual acuity, and clinical history.
Intravitreal anti-VEGF injections are the first-line treatment for myopic choroidal neovascularization. Anti-VEGF stands for anti-vascular endothelial growth factor, referring to a class of medications that block the signal driving abnormal blood vessel growth. These medications are delivered directly into the eye in a carefully controlled clinical setting. They suppress new vessel growth, reduce leakage of fluid and blood beneath the retina, and allow the CNV to regress. Myopic CNV generally responds well to anti-VEGF therapy and typically requires fewer injections than CNV associated with age-related macular degeneration. After initial control is achieved, treatment is usually continued on an as-needed basis, with the timing of each additional injection guided by OCT findings and visual acuity at each follow-up visit.
Vitrectomy surgery may be recommended when myopic traction maculopathy is progressive or causing significant visual decline that is not expected to stabilize. During vitrectomy, the vitreous gel is carefully removed and the tractional forces on the macula are released. The surgeon may also peel the internal limiting membrane to reduce ongoing pulling on the retinal surface. For select patients with certain patterns of myopic traction, macular buckling (a procedure that reshapes the posterior scleral wall to reduce mechanical stress) may also be considered. The choice of surgical approach depends on the specific type and severity of the traction and the anatomy of the individual eye.
At present, there are no established treatments to reverse or halt the progression of macular atrophy in pathologic myopia. Management focuses on monitoring the atrophy with regular imaging, treating any newly developed CNV promptly, and connecting patients with low vision rehabilitation services when central vision loss significantly affects daily activities. Clinical research into potential therapies for atrophic macular disease is ongoing, and participation in a research program may offer access to emerging treatments for patients who qualify.
What to Expect Over Time
Pathologic myopia requires a long-term perspective. Understanding what to expect after treatment and how to stay ahead of disease progression helps you remain an active and informed partner in your own care.
Many patients with myopic CNV experience meaningful visual improvement after anti-VEGF treatment, particularly when treatment begins promptly. The abnormal vessels regress, subretinal fluid resolves, and visual clarity often improves. However, macular atrophy frequently develops around the site of treated CNV in the years that follow, and this atrophic progression is driven by the underlying structural disease in the eye, not by the treatment itself. Long-term follow-up remains essential even after a successful treatment response, so that new complications can be identified and addressed as early as possible.
Patients with pathologic myopia need ongoing retinal surveillance throughout their lives. Your retina specialist will schedule follow-up visits at intervals appropriate for your current level of disease activity, typically including OCT imaging to track atrophy, detect new CNV, or identify developing traction changes. Between clinic visits, daily monitoring with an Amsler grid (a simple printed grid used to detect distortion or blind spots in central vision) is an important part of home surveillance. Any new distortion or sudden change in vision should prompt same-day contact with your retina specialist rather than waiting for your next scheduled appointment.
Living with Pathologic Myopia
While the structural changes of pathologic myopia cannot be reversed, consistent monitoring and timely treatment of complications can help preserve the best possible vision over time. There are also practical steps you can take to support your eye health on an ongoing basis.
Wearing your prescribed corrective lenses supports your best possible functional vision and reduces unnecessary strain. Because eyes with high myopia are structurally more vulnerable to retinal tears and detachment, protecting them from physical trauma is especially important. If you ever experience a sudden shower of new floaters, flashes of light in your peripheral vision, or a curtain-like shadow moving across your visual field, seek urgent evaluation right away. These can be signs of a retinal tear or detachment, which are ophthalmologic emergencies requiring immediate attention.
If macular atrophy progresses to the point where central vision loss limits daily activities, low vision rehabilitation can make a meaningful difference in quality of life. Low vision specialists work with patients to maximize functional vision through magnification devices, specialized lighting, screen-reading and text-enlargement technologies, and other adaptive tools. Your retina specialist can provide a referral to low vision services when it becomes appropriate for your situation.
Frequently Asked Questions
Here are answers to the questions our patients ask most often about pathologic myopia and myopic macular disease.
High myopia refers to a significant degree of nearsightedness (generally greater than six diopters) in a longer-than-normal eye. Pathologic myopia is a subset of high myopia in which the excessive elongation causes degenerative structural changes, such as posterior staphyloma, lacquer cracks, CNV, macular atrophy, or traction maculopathy. Not every person with high myopia develops pathologic changes, but the risk increases with greater axial length. This distinction matters because patients with pathologic findings require specialized retinal monitoring even when their corrected visual acuity still appears adequate to them.
The number of injections depends on how actively the CNV is leaking, how well your eye responds to treatment, and whether the disease becomes and stays quiescent. Myopic CNV tends to respond more quickly than CNV from age-related macular degeneration, and many patients achieve good control with a relatively small number of treatments. After initial stabilization, injections are typically given on an as-needed basis rather than a fixed monthly schedule, with your retina specialist reassessing at each visit using OCT imaging and visual acuity testing to guide the decision.
Once pathologic myopia has developed, the structural changes in the eye cannot be reversed. However, there is growing clinical interest in slowing myopia progression during childhood through strategies such as increased outdoor time and certain pharmacologic approaches to myopia control. Reducing the rate of eye elongation in childhood may lower the probability of reaching the extreme axial lengths associated with pathologic changes in adulthood. If a child in your family has rapidly progressing myopia, a conversation with their eye care provider about myopia management options is a reasonable and worthwhile step.
This is a common and understandably frustrating concern. When anti-VEGF treatment works well, the CNV regresses and vision often improves. However, the underlying pathologic process in the eye continues independently of the treatment. Macular atrophy frequently develops in the area surrounding the previously treated CNV over subsequent years, gradually reducing photoreceptor function in that region. This is one key reason why long-term retinal monitoring remains important even after a good initial treatment response. Catching any new CNV or additional complications early continues to offer the best opportunity for meaningful intervention.
Contact your retina specialist urgently if you notice a sudden dark spot appearing in your central vision, sudden distortion of straight lines that were previously clear, a new and significant shower of floaters, flashes of light in your peripheral vision, or a curtain-like shadow in any part of your visual field. These symptoms can indicate new CNV, a developing macular hole, a retinal tear, or a retinal detachment, all of which benefit from rapid evaluation and, when needed, prompt treatment. When in doubt, contact your care team the same day rather than waiting.
Expert Retina Care at New England Retina Associates
At New England Retina Associates, our team of fellowship-trained vitreoretinal surgeons provides specialized, personalized care for patients throughout Connecticut living with pathologic myopia and myopic macular disease. Whether you are newly diagnosed, referred by your optometrist or ophthalmologist, or have been managing this condition for years, we are here to help you understand your options and protect your vision with the most current, evidence-based approaches. We welcome both referred and self-referred patients at all four of our offices, including urgent and emergency appointments, and are committed to delivering expert retinal care close to where you live.
30 Years of Care & Commitment
